866-997-4948(US-Canada Toll Free)

Hypercholesterolemia - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Metabolic Disorders

No. of Pages : 120 Pages


Global Markets Directs, \'Hypercholesterolemia Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hypercholesterolemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercholesterolemia. Hypercholesterolemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hypercholesterolemia.
  • A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hypercholesterolemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Hypercholesterolemia Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Hypercholesterolemia 11
Hypercholesterolemia Therapeutics under Development by Companies 13
Hypercholesterolemia Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Hypercholesterolemia Therapeutics - Products under Development by Companies 21
Hypercholesterolemia Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Hypercholesterolemia Therapeutics Development 24
Bristol-Myers Squibb Company 24
Johnson & Johnson 25
Amgen Inc. 26
Eli Lilly and Company 27
Tekmira Pharmaceuticals Corp. 28
Merck & Co., Inc. 29
Pfizer Inc. 30
Santaris Pharma A/S 31
Alnylam Pharmaceuticals, Inc 32
Regeneron Pharmaceuticals, Inc. 33
Spherix Incorporated 34
Ache Laboratorios Farmaceuticos S/A 35
Catabasis Pharmaceuticals, Inc. 36
PepTcell Limited 37
Relypsa, Inc. 38
Esperion Therapeutics, Inc. 39
Serometrix, LLC 40
FORMAC Pharmaceuticals N.V. 41
Madeira Therapeutics 42
Hypercholesterolemia - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
SPC-4955 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MGL-3196 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ALN-PCS - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ALN-PCS - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TKM-ApoB - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ETC-1002 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
alirocumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
(ezetimibe + atorvastatin calcium) - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
alfadex - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
evolocumab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BMS-770767 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PF-04950615 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
RLY-106 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
atorvastatin calcium - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ezetimibe - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
(SPX-106 + D-tagatose) - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
BMS-962476 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
1D05-Fab - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
(ezetimibe + rosuvastatin calcium) - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
LY-3015014 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
HeartVax - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PF-05335810 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
BMS-852927 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PCSK-9 Program - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
EGF-A Peptide - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SX-PCK9 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
CAT-2003 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
TP-806 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
fenofibrate - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Aplexone - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
DYB-186 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
simvastatin - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
pravastatin sodium - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
BC-1028 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Compound-3 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
LUM-002 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Hypercholesterolemia Therapeutics - Drug Profile Updates 93
Hypercholesterolemia Therapeutics - Discontinued Products 108
Hypercholesterolemia Therapeutics - Dormant Products 109
Hypercholesterolemia - Product Development Milestones 111
Featured News & Press Releases 111
Sep 03, 2013: Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia 111
Aug 31, 2013: Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 112
Aug 30, 2013: Esperion Therapeutics to Host Conference Call on September 3, 2013 to Announce Top-line Results from a Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia 113
Aug 28, 2013: Catabasis to Present Phase 1 Data from Oral SMART Linker Conjugate CAT-2003 at Upcoming Conference 114
Aug 21, 2013: Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Hypertriglyceridemia and Hypercholesterolemia 114
Jun 07, 2013: Esperion Therapeutics\'s ETC-1002 Meets Primary Endpoint In Phase II Study In Patients With Hypercholesterolemia 115
May 02, 2013: Esperion\'s ETC-1002 Meets Primary Endpoint In Phase II Study In Hypercholesterolemic Patients With Type 2 Diabetes 116
Mar 25, 2013: AstraZeneca Settles Litigation Over Crestor Patent 117
Mar 11, 2013: Alternative Cholesterol Lowering Drug Effective In Patients Who Cant Tolerate Other Statins, Study Finds 117
Feb 04, 2013: US Consumers Approach Court To Consider Recall Of Ranbaxy\'s Generic Lipitor 118

Appendix 119
Methodology 119
Coverage 119
Secondary Research 119
Primary Research 119
Expert Panel Validation 119
Contact Us 120
Disclaimer 120

List of Table


Number of Products Under Development for Hypercholesterolemia, H2 2013 11
Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2013 12
Number of Products under Development by Companies, H2 2013 14
Number of Products under Development by Companies, H2 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2013 16
Comparative Analysis by Late Stage Development, H2 2013 17
Comparative Analysis by Mid Clinical Stage Development, H2 2013 18
Comparative Analysis by Early Clinical Stage Development, H2 2013 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 20
Products under Development by Companies, H2 2013 21
Products under Development by Companies, H2 2013 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2013 23
Bristol-Myers Squibb Company, H2 2013 24
Johnson & Johnson, H2 2013 25
Amgen Inc., H2 2013 26
Eli Lilly and Company, H2 2013 27
Tekmira Pharmaceuticals Corp., H2 2013 28
Merck & Co., Inc., H2 2013 29
Pfizer Inc., H2 2013 30
Santaris Pharma A/S, H2 2013 31
Alnylam Pharmaceuticals, Inc, H2 2013 32
Regeneron Pharmaceuticals, Inc., H2 2013 33
Spherix Incorporated, H2 2013 34
Ache Laboratorios Farmaceuticos S/A, H2 2013 35
Catabasis Pharmaceuticals, Inc., H2 2013 36
PepTcell Limited, H2 2013 37
Relypsa, Inc., H2 2013 38
Esperion Therapeutics, Inc., H2 2013 39
Serometrix, LLC, H2 2013 40
FORMAC Pharmaceuticals N.V., H2 2013 41
Madeira Therapeutics, H2 2013 42
Assessment by Monotherapy Products, H2 2013 43
Assessment by Combination Products, H2 2013 44
Assessment by Stage and Route of Administration, H2 2013 46
Assessment by Stage and Molecule Type, H2 2013 48
Hypercholesterolemia Therapeutics - Drug Profile Updates 93
Hypercholesterolemia Therapeutics - Discontinued Products 108
Hypercholesterolemia Therapeutics - Dormant Products 109
Hypercholesterolemia Therapeutics - Dormant Products (Contd..1) 110

List of Chart


Number of Products under Development for Hypercholesterolemia, H2 2013 11
Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 16
Late Stage Products, H2 2013 17
Mid Clinical Stage Products, H2 2013 18
Early Clinical Stage Products, H2 2013 19
Discovery and Pre-Clinical Stage Products, H2 2013 20
Assessment by Monotherapy Products, H2 2013 43
Assessment by Combination Products, H2 2013 44
Assessment by Route of Administration, H2 2013 45
Assessment by Stage and Route of Administration, H2 2013 46
Assessment by Molecule Type, H2 2013 47
Assessment by Stage and Molecule Type, H2 2013 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *